See the DrugPatentWatch profile for Nerlynx
Information regarding Nerlynx's availability and approval in Australia is limited. Clinical trial data and regulatory approvals in other regions may provide insights into its potential use.
What is Nerlynx used for?
Nerlynx (neratinib) is a medication used to treat certain types of early-stage HER2-positive breast cancer [1]. It is prescribed as extended adjuvant treatment for patients who have already received prior treatment with trastuzumab-based therapy [1]. The drug works by inhibiting human epidermal growth factor receptor 2 (HER2) and other kinases involved in cancer cell growth and survival [1].
When was Nerlynx approved in the US?
The U.S. Food and Drug Administration (FDA) approved Nerlynx in July 2017 [1].
What are the potential side effects of Nerlynx?
The most common side effects reported for Nerlynx include diarrhea, nausea, abdominal pain, fatigue, rash, stomatitis (mouth sores), decreased appetite, and muscle-related pain [1]. Diarrhea is a significant side effect, and management strategies are often recommended [1].
How does Nerlynx work?
Nerlynx is a tyrosine kinase inhibitor that targets HER2, a protein found on some cancer cells [1]. By blocking HER2 and other related proteins, Nerlynx can help slow or stop the growth of these cancer cells [1]. It is taken orally as a tablet [1].
When does Nerlynx's patent expire?
Information on specific patent expiry dates for Nerlynx is not publicly available through the provided context. Drug patent information can often be found through specialized databases [2]. For detailed patent timelines, consulting resources like DrugPatentWatch.com may be necessary [2].
What are the competitors for Nerlynx?
In the realm of HER2-positive breast cancer treatment, other therapies exist that target the HER2 pathway. These can include other HER2-targeted agents like trastuzumab (Herceptin) and pertuzumab (Perjeta) [1]. The landscape of breast cancer treatment is continually evolving with new drug development and therapeutic strategies.
What clinical trials have been conducted for Nerlynx?
The approval of Nerlynx was based on clinical trial data, notably the Phase 3 ExteNET study [1]. This trial evaluated Nerlynx in patients with early-stage HER2-positive breast cancer who had completed at least one year of adjuvant trastuzumab-based therapy [1]. The study assessed the drug's efficacy in reducing the risk of invasive disease recurrence or death [1].
Sources:
[1] https://www.nerlynx.com/
[2] https://drugpatentwatch.com/